The price cuts on anti-cancer medicines, set to take effect from November 9, 2026, reflect pricing details submitted by pharmaceutical manufacturers to the National Pharmaceutical Pricing Authority (NPPA) up to October 27.
Following the official release of the revised Maximum Retail Price (MRP) list covering 543 brands, the Delhi based Retail Distribution Chemists Alliance (RDCA), affiliated with the All-India Organisation of Chemists and Druggists (AIOCD), has issued an urgent compliance notification to its network of stockists, clearing and forwarding agents (CFAs), company depots, and retail outlets.
The NPPA's regulatory move forms part of the ongoing Trade Margin Rationalisation (TMR) exercise for 137 identified non-scheduled anti-cancer drugs, implemented under Paragraph 19 of the Drugs (Prices Control) Order, 2013. By capping trade margins at 30 percent, the government aims to eliminate excessive markups and reduce out-of-pocket healthcare expenses for cancer patients across the country.
Sandeep Nangia, president of the RDCA, has directed all pharmaceutical trade members in the national capital to immediately initiate a line-by-line verification of the revised MRP list. Emphasizing that price reductions vary significantly depending on the brand, strength, formulation, and pack size, Nangia cautioned distributors and chemists against assuming uniform percentage cuts across similar generic molecules.
The published list demonstrates sharp price reductions across high-value oncology therapeutics. For instance, anastrozole 1 mg (10 tablets) under the brand Anarzole sees a reduction from Rs. 695.76 to Rs. 73.00, representing an 89.5 per cent drop. Similarly, bevacizumab 100 mg/4 ml injection (Bevacizab) drops by 72.8 per cent from Rs. 21,767.70 to Rs. 5,930.13 per vial, while significant cuts also apply to brands of azacitidine, denosumab, enzalutamide, erlotinib, fludarabine, and fulvestrant.
To prevent financial mismatches, trade members have been advised to review their existing inventories at depots, warehouses, and retail counters immediately. Stockists and distributors are coordinating with drug manufacturers to obtain authenticated price lists, arrange credit notes, and clarify procedures for price-relabelling on existing printed stock.
Retail pharmacies, hospital dispensaries, and online fulfilment centres must ensure that all billing systems and point-of-sale product master files are fully updated before the November 9 deadline. Charging patients above the notified revised MRP after the effective date will constitute a direct violation of DPCO rules and invite regulatory action.
Despite the widespread inventory adjustments, the trade body and health authorities have underlined the necessity of maintaining an uninterrupted medicine supply chain. Manufacturers and trade channels have been instructed to preserve existing supply volumes so that critical oncology care remains accessible to patients throughout the price transition period.
|